Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Ari Hinkkanen"'
Autor:
Minna Niittykoski, Mikael von und zu Fraunberg, Miika Martikainen, Tuomas Rauramaa, Arto Immonen, Susanna Koponen, Ville Leinonen, Markus Vähä-Koskela, Qiwei Zhang, Florian Kühnel, Ya-Fang Mei, Seppo Ylä-Herttuala, Juha E. Jääskeläinen, Ari Hinkkanen
Publikováno v:
Translational Oncology, Vol 10, Iss 5, Pp 772-779 (2017)
BACKGROUND: Oncolytic adenoviruses show promise in targeting gliomas because they do not replicate in normal brain cells. However, clinical responses occur only in a subset of patients. One explanation could be the heterogenic expression level of vir
Externí odkaz:
https://doaj.org/article/5cf8fbba303a4a31bebd174798fea849
Autor:
Markus Vähä-Koskela, Ari Hinkkanen
Publikováno v:
Biomedicines, Vol 2, Iss 2, Pp 163-194 (2014)
Oncolytic virotherapy has advanced since the days of its conception but therapeutic efficacy in the clinics does not seem to reach the same level as in animal models. One reason is premature oncolytic virus clearance in humans, which is a reasonable
Externí odkaz:
https://doaj.org/article/65256ef432be4c37be7fe9424315e657
Autor:
Maarit Neuvonen, Arunas Kazlauskas, Miika Martikainen, Ari Hinkkanen, Tero Ahola, Kalle Saksela
Publikováno v:
PLoS Pathogens, Vol 7, Iss 11, p e1002383 (2011)
Among the four non-structural proteins of alphaviruses the function of nsP3 is the least well understood. NsP3 is a component of the viral replication complex, and composed of a conserved aminoterminal macro domain implicated in viral RNA synthesis,
Externí odkaz:
https://doaj.org/article/468852f140644a40a1029d116a2dba4d
Autor:
Florian Kühnel, Ari Hinkkanen, Markus Vähä-Koskela, Tuomas Rauramaa, Susanna Koponen, Mikael von und zu Fraunberg, Arto Immonen, Miika Martikainen, Seppo Ylä-Herttuala, Ville Leinonen, Juha E. Jääskeläinen, Ya-Fang Mei, Qiwei Zhang, Minna Niittykoski
Publikováno v:
Translational Oncology, Vol 10, Iss 5, Pp 772-779 (2017)
Translational Oncology
Translational Oncology
BACKGROUND: Oncolytic adenoviruses show promise in targeting gliomas because they do not replicate in normal brain cells. However, clinical responses occur only in a subset of patients. One explanation could be the heterogenic expression level of vir
Autor:
Juha E. Jääskeläinen, Arto Immonen, Markus Vähä-Koskela, Susanna Koponen, Miika Martikainen, Maartje van Geenen, Minna Niittykoski, Mikael von und zu Fraunberg, Ari Hinkkanen, Kalle Saksela, Erkko Ylösmäki
Publikováno v:
Journal of Virology. 89:10637-10647
Glioblastoma is a terminal disease with no effective treatment currently available. Among the new therapy candidates are oncolytic viruses capable of selectively replicating in cancer cells, causing tumor lysis and inducing adaptive immune responses
Autor:
Satu Simell, Mikael Knip, Tuure Kinnunen, Jorma Ilonen, Pekka Arikoski, Outi Vaarala, Ville Simell, Anne Lammi, Olli Simell, Ari Hinkkanen, Jorma Toppari, Riitta Veijola, Sari Paavanen-Huhtala
Publikováno v:
Journal of Pediatric Gastroenterology and Nutrition. 60(5):626-631
Determination of antibodies to synthetic deamidated gliadin peptides (anti-DGPs) may work as an alternative or complement the commonly used test for tissue transglutaminase antibodies (TGA) in the diagnosis of celiac disease (CD). We analyzed the per
Autor:
Janne Ruotsalainen, Jari E. Heikkilä, Pirkko Härkönen, Johanna Tuomela, Miika Martikainen, Ari Hinkkanen, Magnus Essand
Publikováno v:
British Journal of Cancer
Background: Despite recent therapeutic and diagnostic advances, prostate cancer remains the second leading cause of cancer-related deaths among men in the Western world. Oncolytic viruses that replicate selectively in tumour cells represent a novel t
Autor:
Ari Hinkkanen, Markus Vähä-Koskela
Publikováno v:
Biomedicines
Biomedicines, Vol 2, Iss 2, Pp 163-194 (2014)
Biomedicines, Vol 2, Iss 2, Pp 163-194 (2014)
Oncolytic virotherapy has advanced since the days of its conception but therapeutic efficacy in the clinics does not seem to reach the same level as in animal models. One reason is premature oncolytic virus clearance in humans, which is a reasonable
Autor:
Pekka Poutiainen, Jorma J. Palvimo, Ari Hinkkanen, Petri A. Turhanen, Juha Pulkkinen, Reino Laatikainen, Teemu J. Rönkkö, Ale Närvänen, Janne Weisell
Publikováno v:
Bioconjugate Chemistry. 25:4-10
In this paper, novel firefly luciferase-specific inhibitor compounds (FLICs) are evaluated as potential tools for cellular trafficking of transporter conjugates. As a proof-of-concept, we designed FLICs that were suitable for solid phase peptide synt
Autor:
Tytti Aaltonen, Ari Hinkkanen, Minna Niittykoski, Tuulia Huhtala, Janne Ruotsalainen, John C. Bell, Markus Vähä-Koskela, Miika Martikainen, Jari E. Heikkilä
Publikováno v:
Molecular Therapy. 20:1529-1539
In our recent study, replicative alphaviral vector VA7 was found to be effective against orthotopic human U87-glioma xenografts in an athymic mouse model eradicating the tumors with single intravenous (i.v.) injection. Here, we tested the efficacy of